A Spanish public-sector model aims to improve patient access to CAR-T therapy using hospital exemption manufacturing pathways, targeting faster delivery for eligible patients. Presenters described a manufacturing platform developed through collaboration between academic and healthcare stakeholders in Spain. The approach is framed around reducing infrastructure and lead-time barriers by leveraging localized production under regulatory flexibility, with a focus on therapies such as ARI-0001 targeting CD19 in relapsed acute lymphoblastic leukemia. The company said pilot trials are assessing feasibility and safety for local delivery and production. As CAR-T demand grows, these access-focused manufacturing models may become key for countries where reimbursement and logistics limit utilization.